Cardiac biomarker-based risk stratification algorithm in patients with severe COVID-19.

•Cardiac biomarker measurement in all patients with coronavirus disease 2019 (COVID-19) is not routinely recommended.•It is recommended only when type 1 myocardial infarction or heart failure is strongly suspected on clinical grounds.•We propose a simple cardiac biomarker-based risk-stratification algorithm to be used in patients with severe COVID-19.•This algorithm is likely to aid in triaging, risk-prognostication, and management of patients with severe COVID-19.•The use of this algorithmic approach might also limit infection exposure risk to the attending cardiovascular team.